"Iclusig is a best-in-class drug and a potential first-line therapy with very compelling efficacy," said analyst Michael J. Yee with RBC Capital Markets in San Francisco. "What's very interesting about Ariad is that they are the rare biotech that has decided to retain worldwide commercial rights to their drugs. That could be particularly valuable in the future."
News 
Market Data 
Discover 
